English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

RA is a chronic multisystem inflammatory disorder with a prevalence of 0.5 1% in the general population. The management of RA has evolved considerably in the last few decades and newer therapies continue to be developed. Tocilizumab (TCZ) [1] is a humanized anti-IL-6 receptor (anti-IL-6R) antibody licensed for use in combination with MTX for the treatment of moderate to severe RA in adult patients who have either responded inadequately to or who were intolerant to previous therapy with one or more DMARDs or TNF antagonists. In such patients, TCZ can be administered as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate. Several large randomized controlled trials (RCTs) have demonstrated the efficacy and tolerability of TCZ in the treatment of RA.

The 2013 BSR and BHPR guideline for the use of intravenous tocilizumab in the treatment of adult patients with rheumatoid arthritis